Home › Funds › Red Spruce Capital, LLC › NBIX
Red Spruce Capital, LLC position in NBIX
NEUROCRINE BIOSCIENCES INC · Health Care
Red Spruce Capital, LLC reported holding 16,754 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$2.4M, representing 0.84% of its reported portfolio and ranking #42 among its reported holdings. Red Spruce Capital, LLC has disclosed NBIX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR
How Red Spruce Capital, LLC's NBIX position evolved
Red Spruce Capital, LLC first disclosed a stake in NBIX in Q3 2023 at 15,925 shares (US$1.8M). The position peaked in Q2 2026 at 16,693 shares, worth US$2.8M. Across 13 filings, Red Spruce Capital, LLC increased the stake 3 time(s), trimmed it 4 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 16,754 shares valued at US$2.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 15.93K | $1.79M | New |
| Q4 2023 | 16.03K | $2.11M | Add |
| Q1 2024 | 16.03K | $2.21M | Hold |
| Q2 2024 | 16.15K | $2.22M | Add |
| Q3 2024 | 15.91K | $1.83M | Reduce |
| Q4 2024 | 15.92K | $2.17M | Hold |
| Q1 2025 | 15.58K | $1.72M | Reduce |
| Q2 2025 | 15.58K | $1.96M | Hold |
| Q3 2025 | 17.37K | $2.44M | Add |
| Q4 2025 | 17.16K | $2.43M | Reduce |
| Q1 2026 | 17.21K | $2.27M | Hold |
| Q2 2026 | 16.69K | $2.81M | Reduce |
| Q3 2026 | 16.75K | $2.38M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NBIX and 13F data
NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 34 other funds we track also report a position in NBIX — the largest reported positions include Renaissance Technologies (US$393.7M), Two Sigma Investments (US$349.9M), Vestal Point Capital, LP (US$316.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NBIX
- Renaissance Technologies 2.34M sh · $393.68M · Q2 2026
- Two Sigma Investments 2.08M sh · $349.92M · Q2 2026
- Vestal Point Capital, LP 1.88M sh · $316.85M · Q2 2026
- RTW INVESTMENTS, LP 1.27M sh · $213.69M · Q2 2026
- IEQ CAPITAL, LLC 640.30K sh · $107.91M · Q2 2026
More on Red Spruce Capital, LLC
FAQ
How long has Red Spruce Capital, LLC held NBIX?
Red Spruce Capital, LLC has disclosed NBIX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Red Spruce Capital, LLC's current position in NBIX?
As of Q3 2026, Red Spruce Capital, LLC holds 16.75K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $2.38M, representing 0.84% of its reported portfolio and ranking #42.
Has Red Spruce Capital, LLC been buying or selling NBIX?
In the latest 13F filing (Q3 2026), Red Spruce Capital, LLC held unchanged its position in NBIX. The position peaked in Q2 2026 at 16.69K shares.
Which other funds hold NBIX?
Other major institutional holders of NBIX include Renaissance Technologies, Two Sigma Investments, Vestal Point Capital, LP, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.